Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. More Details
+ 1 more risk
Flawless balance sheet with limited growth.
Share Price & News
How has Sintx Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SINT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: SINT's weekly volatility has decreased from 30% to 20% over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: SINT exceeded the US Medical Equipment industry which returned 33.8% over the past year.
Return vs Market: SINT exceeded the US Market which returned 36.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Sintx Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall StSintx Technologies, Inc. (NASDAQ:SINT): What Does Its Beta Value Mean For Your Portfolio?
10 months ago | Simply Wall StHow Much Did Sintx Technologies, Inc.'s (NASDAQ:SINT) CEO Pocket Last Year?
1 year ago | Simply Wall StCompanies Like Sintx Technologies (NASDAQ:SINT) Can Be Considered Quite Risky
Is Sintx Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SINT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SINT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SINT is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: SINT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SINT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SINT is good value based on its PB Ratio (1.8x) compared to the US Medical Equipment industry average (5.1x).
How is Sintx Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SINT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SINT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SINT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SINT's revenue (82.4% per year) is forecast to grow faster than the US market (10.4% per year).
High Growth Revenue: SINT's revenue (82.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SINT's Return on Equity is forecast to be high in 3 years time
How has Sintx Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SINT is currently unprofitable.
Growing Profit Margin: SINT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SINT is unprofitable, but has reduced losses over the past 5 years at a rate of 12.8% per year.
Accelerating Growth: Unable to compare SINT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SINT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5.7%).
Return on Equity
High ROE: SINT has a negative Return on Equity (-22.84%), as it is currently unprofitable.
How is Sintx Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: SINT's short term assets ($29.6M) exceed its short term liabilities ($3.4M).
Long Term Liabilities: SINT's short term assets ($29.6M) exceed its long term liabilities ($1.7M).
Debt to Equity History and Analysis
Debt Level: SINT's debt to equity ratio (1.4%) is considered satisfactory.
Reducing Debt: SINT had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SINT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SINT has sufficient cash runway for 2.9 years if free cash flow continues to grow at historical rates of 13.9% each year.
What is Sintx Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SINT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SINT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SINT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SINT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SINT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
B. Bal (58 yo)
Dr. B. Sonny Bal, M.D., J.D., MBA, PhD, has been the Chief Executive Officer and President of Sintx Technologies, Inc. (formerly known as Amedica Corporation) since October 2014 and its Chairman since Augu...
CEO Compensation Analysis
Compensation vs Market: B.'s total compensation ($USD401.23K) is about average for companies of similar size in the US market ($USD511.69K).
Compensation vs Earnings: B.'s compensation has been consistent with company performance over the past year.
|Chief Operating Officer||5.75yrs||US$242.15k||0.022% |
|Chief Scientific Officer||3.08yrs||US$249.31k||0.000050% |
Experienced Management: SINT's management team is seasoned and experienced (5.8 years average tenure).
|Independent Director||10.42yrs||US$122.00k||0.00028% |
|Independent Director||6.33yrs||US$42.00k||0% |
|Independent Director||7.08yrs||US$42.00k||no data|
|Independent Director||1yr||no data||no data|
|Member of Scientific Advisory Board||5.42yrs||no data||no data|
Experienced Board: SINT's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 949.8%.
Sintx Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Sintx Technologies, Inc.
- Ticker: SINT
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$52.380m
- Shares outstanding: 25.55m
- Website: https://www.sintx.com
Number of Employees
- Sintx Technologies, Inc.
- 1885 West 2100 South
- Salt Lake City
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SINT||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Feb 2014|
|111N||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2014|
Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, a...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/02/28 23:46|
|End of Day Share Price||2021/02/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.